In Brief: Medi-Physics/Amersham Healthcare
Executive Summary
Medi-Physics/Amersham Healthcare: U.S. arm of U.K. parent Amersham signs Adenoscan distribution agreement with Fujisawa USA, which licenses the adenosine injection from Medco Research. Adenoscan was approved May 18 for evaluating cardiac function in patients who cannot undergo a stress test ("The Pink Sheet" May 22, T&G-3). The agreement with Fujisawa will allow Medi-Physics to distribute Adenoscan through its Pharmacy Network of "more than 115 radiopharmacies to their customers," Arlington Heights, Ill.-based Medi-Physics reports. Medi-Physics said July 17 it received an "approvable" letter from FDA for its cardiac perfusion agent Myoview (kit for the preparation of technetium Tc-99m tetrofosmin)...